Financing channel feed – Endpoints News

Financing channel feed

Chinese pharma powerhouse Hansoh joins fledgling biotechs in the Hong Kong IPO line

7 years ago

Circled by rival pharma giants and a biotech powerhouse, Kodiak asks for a $100M-plus IPO for new eye drug

7 years ago

MPM, Novartis lead a big launch round for Kazumi Shiosaki’s latest biotech startup coming out of Harvard

7 years ago

New investors pool $120M to bankroll Allogene's off-the-shelf CAR-T pipeline in drive to stay in the lead

7 years ago

Allied with Roche and AstraZeneca, 4D Molecular bags $90M round for its gene therapy pipeline work

7 years ago

PhaseBio raises $34M to test orphan disease strategy — focusing first on AstraZeneca drug

7 years ago

Eyeing an IPO, Fulcrum execs nail down an $80M round on the way to the clinic with their first gene-regulating drug

7 years ago

Partnering with Amgen vet Sean Harper, veteran VC Beth Seidenberg unveils a $320M fund and a unique focus on…wait for it…LA

7 years ago

Oxford spinout Evox grabs a $45M bankroll to advance to the clinic with new exosome tech

7 years ago

Illustrious Cambridge scientists join forces with $129M fund to bet on long plays in biotech

7 years ago

Qiming, Hillhouse bet on Jacobio's nascent pipeline of first-in-class drug hopefuls in $55M round

7 years ago

Allied with Genentech and Pfizer on discovery deals, protein degradation crew at Arvinas looks for $100M IPO ahead of PhI start

7 years ago

Closely allied with (both) Mercks and Celgene, Sutro CEO Bill Newell is laying out all his cards in a new IPO

7 years ago

As the maiden biotech IPO on the HKEX fizzles, some investment experts see an upside in tempering the hype

7 years ago

GSK spinout KaNDy raises $32M to fund a breakthrough shot at a women's health drug

7 years ago

Alzheon IPO take two: Will investors back a downsized offering from an Alzheimer’s biotech?

7 years ago

Vivek Ramaswamy bags $100M in risk capital to back his latest PhIII gamble at Dermavant — while Urovant dives into gene therapy

7 years ago

Harbour BioMed follows cancer drug deals with a hefty $85M Series B backed by Singapore's GIC

7 years ago

Y-mAbs’ story comes into the light: a shipping tycoon, the MSK researcher, a partial hold and a $92M IPO gamble

7 years ago

Newly partnered with bluebird, Gritstone seeks $80M IPO in final dash for clinic

7 years ago

Japanese billionaire Hiroshi Mikitani bankrolls Aspyrian with a $150M mega-round, backing a global rollout plan for PhIII cancer therapy

7 years ago

Newborn biobetter, biosimilar maker Mabpharm pitches the latest biotech IPO in Hong Kong

7 years ago

Construction sources buzzing about a new set of headaches and hurdles facing AstraZeneca’s beleaguered, $650M HQ project

7 years ago

Right on the heels of $150M raise, Ascentage files the latest in a rush of HKEX biotech IPOs — but is the market too jittery?

7 years ago

First page Previous page 122 123 124125126 127 128 Next page Last page